TourbahALebrun-FrenayCEdanG, et al. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study. Mult Scler2016; 22(13): 1719–1731.
2.
PikettyMLPrieDSedelF, et al. High-dose biotin therapy leading to false biochemical endocrine profiles: Validation of a simple method to overcome biotin interference. Clin Chem Lab Med2017; 55(6): 817–825.
3.
MontalbanXHauserSLKapposL, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med2017; 376(3): 209–220.
4.
MikulskaMLaniniSGudiolC, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: An infectious diseases perspective (agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52). Clin Microbiol Infect2018; 24(Suppl. 2): S71–S82.
5.
TrambasCLuZYenT, et al. Depletion of biotin using streptavidin-coated microparticles: A validated solution to the problem of biotin interference in streptavidin-biotin immunoassays. Ann Clin Biochem2018; 55(2): 216–226.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
